2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 230

Hydroxy-3-Methylglutaryl-Coenzyme A Reductase (HMGCoR) Antibody in Necrotizing Myopathy and the Role of Statins
Abstract Number: 2482

Hydroxychloroquine Has Lipid-Lowering Effects in US Veterans with Rheumatoid Arthritis
Abstract Number: 1260

Hydroxychloroquine Reduces the Risk of Coronary Artery Disease in Patients with Rheumatoid Arthritis
Abstract Number: 2569

Hydroxychloroquine Reduces Thrombosis in Systemic Lupus Erythematosus, Particularly in Antiphospholipid Positive Patients
Abstract Number: 2268

Hyperacetylation of Histone H4 in Systemic Lupus Erythematosus
Abstract Number: 1773

Hyperammaglobulinemia in Primary Sjögren’s Syndrome Is Induced by Triggering of TLR7 and 9
Abstract Number: 2528

Hypertrophic Pachymeningitis: IgG4-Related Disease Is A Common Etiology
Abstract Number: 1858

Hypervigiliance in Fibromyalgia
Abstract Number: 2262

Hypogammaglobulinemia in Pediatric Systemic Lupus Erythematosus
Abstract Number: 1967

Hypophosphatemic Osteomalacia Induced by Tenofovir in Patients with Human Immunodeficiency Virus Infection
Abstract Number: 415

Hypoxia-Induced Endogenous Prostaglandin E2 Negatively Regulates Hypoxia-Enhanced Aberrant Overgrowth of Rheumatoid Synovial Tissue
Abstract Number: 1065

Hypoxia-Inducible Factor-1α: Trigger of Toll-Like Receptor Signalling-Engaged Inflammation in Rheumatoid Arthritis
Abstract Number: 432

Identification and Characterization of Fibrinogen-Specific T Cells in Patients with Rheumatoid Arthritis
Abstract Number: 1810

Identification and Characterization of Synthetic Small Molecule Macrocycle Antagonists of Human IL17A
Abstract Number: 18

Identification of 14-3-3å As a New Subchondral Bone Mediator Involved in Cartilage Degradation During Osteoarthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].